Latest news with #DanielWilson
Telegraph
27-05-2025
- Entertainment
- Telegraph
Man denies breaching restraining order by contacting ex-007 producer
A man has denied 11 counts of breaching a restraining order by contacting former James Bond producer Barbara Broccoli. Daniel Wilson was prohibited from contacting Broccoli, 64, by an order put in place at Isleworth Crown Court on July 3 2017. Broccoli, 64, and her half-brother Michael G Wilson, 83, produced the James Bond franchise after the death of Albert 'Cubby' Broccoli in 1996 until February this year. Amazon MGM Studios will gain creative control. It is alleged that Mr Wilson, 36, from Lambeth, south London, acted in breach of the restraining order by attempting to contact Broccoli 'without reasonable excuse' on 11 dates between April 2022 and April last year. Mr Wilson appeared on video link and pleaded not guilty to each charge at Southwark Crown Court on Tuesday. The court heard Mr Wilson, who wore glasses and a patterned jacket during the hearing, is currently in hospital. Bail conditions had been put in place at an earlier hearing and Judge Sally-Ann Hales KC ordered that they would continue. She told Mr Wilson he could not 'be in possession of any device that can access the internet' or contact Broccoli directly or indirectly. He must also live and sleep each night in a location directed by the NHS, she said. His trial was set for July 19 2027, and Judge Hales added: 'I'm afraid that is the earliest date that the court can accommodate.' She granted that Broccoli can give evidence behind screens 'given the a nature of the allegations'. Mr Wilson is charged with acting in breach of the restraining order on April 1 and 19, May 19 and 25, June 30 and July 6 in 2022. He is also accused of doing so on March 10, April 12, 17, 20 and 22 in 2024. The 007 franchise had been controlled by members of the Broccoli family, either single-handedly or in partnership with others, since the first Bond film Dr No in 1962. Broccoli and her half-brother produced the past nine Bond films, including Casino Royale, Quantum of Solace, Spectre and No Time to Die. They have been made CBEs and won the outstanding British film Bafta for 2012's Skyfall along with director Sir Sam Mendes. Amazon gained creative control of the British spy franchise following a deal which saw Eon Productions, run by Wilson and Broccoli, become co-owners with Amazon MGM Studios.
Daily Mail
27-05-2025
- Entertainment
- Daily Mail
Man, 36, denies breaching restraining order against former James Bond producer Barbara Broccoli by attempting to contact her at least 11 times
A man has denied breaching a restraining order against former James Bond producer Barbara Broccoli. Daniel Wilson, 36, denied 11 counts of violating the order which prohibited him from contacting the producer. The order was put in place at Isleworth Crown Court on July 3, 2017, and Mr Wilson allegedly attempted to contact Broccoli 'without reasonable excuse' on 11 dates between April 2022 and April last year. Mr Wilson, from Lambeth, appeared on video link at Southwark Crown Court on Tuesday and pleaded not guilty to each charge. The court heard he is currently staying in hospital and that the bail conditions that had been put in place at an earlier hearing would continue. Judge Sally-Ann Hales KC told Wilson he cannot 'be in possession of any device that can access the internet' or contact Broccoli directly or indirectly. He must also live and sleep each night in a location directed by the NHS, she said. His trial was set for July 19 2027 and Judge Hales added: 'I'm afraid that is the earliest date that the court can accommodate.' She granted that Broccoli can give evidence behind screens 'given the a nature of the allegations'. Wilson was charged with acting in breach of the restraining order on April 1, April 19, May 19, May 25, June 30 and July 6 2022. He is also accused of doing so on March 10, April 12, April 17, April 20 and April 22 2024. The 007 franchise had been controlled by members of the Broccoli family, either single-handedly or in partnership with others, since the first 007 movie Dr No in 1962. Ms Broccoli, 64, and Michael G Wilson, 83, produced the James Bond franchise after the death of Albert 'Cubby' Broccoli until it was announced in February this year that Amazon MGM Studios will gain creative control. Broccoli and her half-brother Wilson produced the last nine Bond films, including Casino Royale, Quantum Of Solace, Spectre and No Time To Die. They have been honoured with CBEs, and won the outstanding British film Bafta for 2012's Skyfall along with director Sir Sam Mendes. Amazon gained creative control of the British spy franchise following a deal which saw Eon Productions, run by Wilson and Broccoli, become co-owners with Amazon MGM Studios.
BBC News
27-05-2025
- Entertainment
- BBC News
Man denies breaking restraining order to contact James Bond boss
A man has denied 11 counts of breaching a restraining order by contacting former James Bond producer Barbara Wilson, 36, was banned from contacting Ms Broccoli in an order issued by Isleworth Crown Court in is alleged Mr Wilson acted in breach of that order by trying to contact Ms Broccoli "without reasonable excuse"11 times between April 2022 and April last Wilson, of Mostyn Road, Lambeth, appeared via video link and pleaded not guilty to each charge at Southwark Crown Court. Ms Broccoli started working for the James Bond franchise when she was 17 - working her way up to producer shortly before the death of her father Albert "Cubby" was announced in February that Amazon MGM Studios will gain creative conditions put in place at an earlier hearing - including that Mr Wilson has no devices to access the internet, and must sleep in a location decided by the NHS - will trial was set for July 2027 - a date the judge said was "the earliest available".The 007 film franchise had been controlled by members of the Broccoli family, either single-handedly or in partnership with others, since the first 007 movie Dr No in 1962.
Yahoo
16-05-2025
- Business
- Yahoo
IRTC Q1 Earnings Call: Outperformance Driven by Zio AT and Primary Care Channel Expansion
Medical technology company iRhythm Technologies (NASDAQ:IRTC) reported Q1 CY2025 results topping the market's revenue expectations , with sales up 20.3% year on year to $158.7 million. The company's full-year revenue guidance of $695 million at the midpoint came in 2% above analysts' estimates. Its non-GAAP loss of $0.96 per share was 2.5% below analysts' consensus estimates. Is now the time to buy IRTC? Find out in our full research report (it's free). Revenue: $158.7 million vs analyst estimates of $153.6 million (20.3% year-on-year growth, 3.3% beat) Adjusted EPS: -$0.96 vs analyst expectations of -$0.94 (2.5% miss) Adjusted EBITDA: -$2.64 million vs analyst estimates of -$5.03 million (-1.7% margin, 47.6% beat) The company lifted its revenue guidance for the full year to $695 million at the midpoint from $680 million, a 2.2% increase Operating Margin: -20.5%, up from -28.9% in the same quarter last year Free Cash Flow was -$17.31 million compared to -$61.81 million in the same quarter last year Market Capitalization: $4.5 billion iRhythm's first quarter results were shaped by accelerated adoption of its Zio AT product and increasing penetration in primary care channels. CEO Quentin Blackford pointed to strong demand from both new and existing accounts, as well as record onboarding of healthcare providers, as key contributors to the robust unit volume growth. Management highlighted the growing share of long-term continuous monitoring prescriptions originating from primary care settings, emphasizing early diagnosis benefits and improved clinical outcomes for patients previously unaware of arrhythmias. Looking ahead, the company's updated full-year guidance reflects confidence in continued momentum from both Zio AT and undiagnosed arrhythmia monitoring through innovative channel partners. CFO Daniel Wilson stated, 'Zio AT performance was a primary driver of our guidance raise, while innovative channel partners are contributing but remain an emerging opportunity.' Management acknowledged macroeconomic uncertainty but maintained that operational efficiencies, product mix, and upstream care pathway expansion are expected to drive sustainable growth for the remainder of the year. Management attributed the quarter's performance to expansion in core U.S. markets, increased adoption among primary care providers, and strong uptake of the Zio AT product. The company also referenced momentum in international markets and ongoing operational efficiency initiatives. Zio AT Momentum: The Zio AT mobile cardiac telemetry device saw significant uptake, benefiting from both new and existing account additions. Management believes features like 14-day continuous wear differentiate it versus competitors, driving retention and market share gains within the MCT segment. Primary Care Channel Expansion: Nearly one third of long-term continuous monitoring volumes now originate from primary care physicians, up from the low 20s percent a year and a half ago. Management credits its 'land-and-expand' strategy for enabling earlier detection and diagnosis of cardiac arrhythmias, particularly among patients with comorbidities who might otherwise be undiagnosed. Innovative Channel Partners: Contribution from value-based care partners focused on undiagnosed arrhythmia monitoring increased, though still represents a low single-digit percentage of total volume. Management described this as an early-stage but high-potential growth avenue for expanding the market beyond traditional cardiology. International Progress and Japan Launch: The company launched Zio in Japan, the world's second-largest ambulatory cardiac monitoring market, albeit at reimbursement rates equivalent to existing Holter monitors. iRhythm aims to generate local clinical evidence to secure higher reimbursement in the future. European markets, especially the UK, continued to deliver record volume. Regulatory and Operational Focus: Ongoing remediation and compliance activities with the FDA, including addressing warning letter observations, remain a top corporate priority. Management expects to complete remediation efforts by the end of 2025 and has allocated resources to ensure uninterrupted product supply in light of tariff and supply chain uncertainties. Management's outlook for the year centers on sustaining Zio AT momentum, expanding the primary care channel, and executing on operational efficiency, while navigating macroeconomic and reimbursement risks. Sustained Zio AT Growth: Expectations for continued above-average growth from the Zio AT product underpin revenue guidance, as management anticipates retention of recent share gains and further penetration in existing accounts. Primary Care and Innovative Partnerships: The company plans to deepen its presence in primary care and value-based care channels, aiming to address a broader population of undiagnosed arrhythmia patients and expand the total addressable market. Tariff and Supply Chain Risks: Management highlighted potential headwinds from tariffs on imported components and supply chain disruptions, but indicated mitigation strategies are underway, including building inventory and exploring supply chain adjustments. Pricing actions will be considered as a secondary lever. Allen Gong (JPMorgan): Asked about drivers behind the guidance raise and confidence for the rest of the year. Management cited sustained Zio AT momentum and a robust pipeline from innovative channel partners but emphasized caution in embedding emerging contributions into guidance. Kallum Titchmarsh (Morgan Stanley): Inquired about the stickiness of Zio AT share gains and how this frames expectations for the upcoming Zio MCT launch. CEO Quentin Blackford noted that established relationships in existing accounts and product features were key to customer retention and future cross-selling potential. Macauley Kilbane (William Blair): Sought clarification on the impact of Epic Aura integration for workflow efficiencies and volume growth. Management reported early signs of increased prescribing patterns but stated these benefits are not yet fully factored into guidance. Suraj Kalia (Oppenheimer): Requested more detail on growth across different business segments. CFO Daniel Wilson explained that Zio AT outpaced company average growth, primary care volumes now exceed one third of total, and innovative channel partners contributed a small but growing share. Sam Eiber (BTIG): Asked about strategies to offset tariff impacts, specifically whether price increases were under consideration. Management replied that supply chain adjustments are the primary mitigation strategy, with pricing actions as a secondary option. Looking ahead, the StockStory team will monitor (1) the trajectory of Zio AT adoption and retention in both existing and new accounts, (2) the pace of expansion and volume contribution from primary care and innovative channel partners, and (3) progress on international launches, particularly in Japan and Europe. Execution on FDA remediation milestones and the timeline for filing and approval of the next-generation Zio MCT device will also be closely watched. iRhythm currently trades at a forward EV-to-EBITDA ratio of 78.7×. At this valuation, is it a buy or sell post earnings? The answer lies in our free research report. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today. Sign in to access your portfolio
RNZ News
14-05-2025
- RNZ News
Nelson schools out of lockdown following 'threatening'email to college, principal says
Photo: RNZ / Nate McKinnon Schools in Nelson have come out of lockdown after a Nayland College received an email threatening violence against students, a school principal says. Police had earlier closed Nayland Road and put cordons in place, which have since been lifted. A person has been spoken to by police. There was no threat to the public after the incident and no further police action was required, police said. Nayland College principal Daniel Wilson said in a statement the school immediately contacted police after receiving the email. "After a thorough assessment, police advised that there was no credible threat, and students were safely released a short time later than usual. "As an added precaution, Broadgreen Intermediate and Nayland Primary were also placed into lockdown," the statement said. In a post on Facebook , councillor for Nelson Māori Ward Kahu PakiPaki said "armed police were called to ensure a threat was not carried out". "Expecting our kids to be making their way home shortly," the post said.
